How old is "too old" for translational research?

Translational Lung Cancer Research

Volumn 3, Issue 2, 2014, Pages 116-119

  Vergnenegre, Alain ^a,b   Corre, Romain ^b,c   Lena, Hervé ^b,c   Le Caer, Hervé ^b,d  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b Groupe Français de Pneumo Cancerologie GFPC   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Service de Pneumologie CH Draguignan   (France)

Author keywords

Antiangiogenic agents; Elderly; Lung cancer; Tyrosine kinase inhibitors (TKIs)

Indexed keywords

EID: 84944357147     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.03.03     Document Type: Review

References (28)

1. Balducci L. Lung cancer and aging, Educational book, ASCO 2005:587-91.
2. NCI. National Cancer Institute, Surveillance Epidemiology and End Results data. 2013; Available online: http://seer.cancer.gov/, October 2013.
3. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224-37.
4. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31.
5. Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 2005;54:129-36.
6. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-smallcell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88.
7. Tam TC, Ho JC, Wong MK, et al. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer. Lung 2013;191:645-54.
8. López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013;153:1194-217.
9. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-400.
10. Langer CJ. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 2009;27:1350-4.
11. Gridelli C, De Marinis F, Di Maio M, et al. Gefitinib as first-line treatment for patients with advanced non-smallcell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Lung Cancer 2011;72:3-8.
12. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26:4253-60.
13. Minegishi Y, Maemondo M, Okinaga S, et al. First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study). J Clin Oncol 2010;28:abstr 7561.
14. Asami K, Koizumi T, Amejima S, et al. First-line gefitinib for elderly patients harboring EGFR mutations. J Clin Oncol 2010;28:abstr e18094.
15. Uruga H, Kishi K, Fujii T, et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med 2010;49:103-7.
16. Goss G, Ferry D, Wierzbicki R, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-smallcell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60.
17. Chen KY, Chen JH, Shih JY, et al. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol 2010;5:82-9.
18. Ebi N, Semba H, Tokunaga SJ, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1166-71.
19. Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced nonsmall cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 2012;7:1417-22.
20. Wu CH, Fan WC, Chen YM, et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 2010;5:376-79.
21. LeCaer H, Greillier L, Corre R, et al. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). Lung Cancer 2012;77:97-103.
22. LeCaer H, Barlesi F, Corre R, et al. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer 2011;105:1123-30.
23. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-5.
24. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
25. Wozniak AJ, Garst J, Jahanzeb M, et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Clin Oncol 2012;28:abstr 7618.
26. Tsao AS, Liu S, Lee JJ, et al. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 2012;7:1645-52.
27. Rosell R, Santarpia M, Moran T, et al. Age-related genetic abnormalities: the Achilles' heel for customizing therapy in elderly lung cancer patients. Personal Med 2007;4:59-72.
28. Rosell R. Pharmacogenomics comes of age in selecting patients for lung cancer treatment. American Society of Clinical Oncology, 42nd. Annual Meeting, Educational Book, 2006:425-30.